Format

Send to:

Choose Destination
See comment in PubMed Commons below
Hepat Mon. 2012 Mar;12(3):168-76. doi: 10.5812/hepatmon.832. Epub 2012 Mar 28.

Hepatitis B immune globulin in liver transplantation prophylaxis: an update.

Author information

  • 1Iranian Hepatitis Network, Tehran, IR Iran.

Abstract

CONTEXT:

Liver transplantation is the best treatment option for end-stage liver disease following hepatitis B (HBV) infection. However, the high rate of recurrence of HBV infection following transplantation is a disadvantage of this option.

EVIDENCE ACQUISITION:

Over the past 2 decades, the gold standard of prophylactic treatment for the prevention of HBV re-infection following liver transplantation has been the administration of low- to high-dose hepatitis B immune globulin (HBIg) along with an antiviral agent to induce passive immunity.

RESULTS:

The effectiveness of HBIg in preventing the recurrence of HBV depends on the dosage, route of administration, and duration of HBIg treatment, and the viremic status at the time of transplantation. There is currently no consensus on a standardized recommendation for therapeutic options that include HBIg administration.

CONCLUSION:

This review attempts to summarize the available data on the feasibility of such options. Most recent studies support the use of long-term combination therapy of HBIg and antiviral NAs (especially new agents).

KEYWORDS:

Hepatitis B Hyperimmune Globulin; Liver Transplantation; Prevention and Control

PMID:
22550524
[PubMed]
PMCID:
PMC3339416
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk